Ovid Therapeutics Q3 revenue slightly beats expectations

Ovid Therapeutics

12/11/2025 12:13

Overview

Ovid Therapeutics Q3 revenue slightly beats analyst expectations

Meg Alexander appointed CEO, effective January 2026

Outlook

Ovid plans Phase 2a trial for OV329 in Q2 2026

Company expects OV350 data in Q4 2025

Ovid anticipates OV4071 clinical trial start in Q2 2026

Result Drivers

Research and development expenses were $5.9 million for the third quarter ended September 30, 2025, compared to $7.9 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$132,000
$131,430 (7 Analysts)
Q3 EPS
-$0.17
Q3 Net Income
-$12.16 mln
Q3 Operating Expenses
$12.66 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Ovid Therapeutics Inc is $4.50, about 70% above its November 11 closing price of $1.35

Press Release: ID:nGNX3mxvZJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)